In this study, we first determined that CLDN6 is an effective target for ovarian cancer and then constructed two types of third-generation CAR-NK cells with different domains targeting CLDN6 to explore their antitumor activity in vivo and in vitro and the effect of regional cell therapy in vivo and to observe the biological characteristics of CAR-NK cells by real-time dynamic imaging of living cells. Here, CLDN6 is linked to ovarian cancer.